Rheumatology International

, Volume 33, Issue 9, pp 2373–2379 | Cite as

Relation of rheumatoid factor and anti-cyclic citrullinated peptide antibody with disease activity in rheumatoid arthritis: cross-sectional study

  • Jung-Yoon Choe
  • Jisuk Bae
  • Hwajeong Lee
  • Sang-Cheol Bae
  • Seong-Kyu Kim
Original Article

Abstract

To analyze the association of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (anti-CCP) with non-remission and with disease activity measures in rheumatoid arthritis (RA). Cross-sectional study of consecutive RA patients. Non-remission was defined as a disease activity score (DAS28) ≥2.6 at study enrollment. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) were additionally measured. Serum titers of RF and anti-CCP were transformed into incremental levels (100/units) and log-transformed levels. Analysis of association with non-remission was done with logistic regression models, with and without adjustment for age, sex, disease duration, and corticoid use. Multiple regression models, raw and similarly adjusted, were used to measure the association of RF and anti-CCP with the disease activity measures. A total of 385 patients were included, of whom 286 (74 %) were not in remission. Log-transformed RF level was associated with an increased risk of non-remission after adjustment (OR = 1.32, 95 % CI 1.04–1.67). This association was especially evident in patients with less than 10 years of disease duration (OR = 1.51, 95 % CI 1.15–1.99) and in those using steroids (OR = 2.06, 95 % CI 1.22–3.48). Serum RF titers and log-transformed RF levels showed a small but significant association with DAS28 score (adjusted beta coefficients 0.002 and 0.18, respectively; both p ≤ 0.01), but neither with SDAI or CDAI nor with anti-CCP antibody. : Log-transformed RF levels might be associated with non-remission in RA, especially in patients with short disease duration or on steroids.

Keywords

Rheumatoid arthritis Rheumatoid factor Anti-CCP antibody Disease activity 

References

  1. 1.
    Houssien DA, Jonsson T, Daview E, Scott DL (1998) Rheumatoid factor isotypes, disease activity and the outcome of rheumatoid arthritis. Comparative effects of different antigens. Scand J Rheumatol 27:46–53PubMedCrossRefGoogle Scholar
  2. 2.
    Bukhari M, Lunt M, Harrison BJ, Scott DGI, Symmons DPM, Silman AJ (2002) Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis. Results from the Norfolk arthritis register study, a large inception cohort. Arthritis Rheum 46:906–912PubMedCrossRefGoogle Scholar
  3. 3.
    Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van’t Hof M et al (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43:1831–1835PubMedCrossRefGoogle Scholar
  4. 4.
    Vencovský J, Machácek S, Sedová L, Kafková J, Gatterová J, Pesáková V et al (2003) Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 62:427–430PubMedCrossRefGoogle Scholar
  5. 5.
    Manfredsdottir VF, Vikingsdottir T, Jonsson T, Geirsson AJ, Kjartansson O, Heimisdottir M (2006) The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 45:734–740CrossRefGoogle Scholar
  6. 6.
    Eberhardt KB, Truedsson L, Pettersson H, Svensson B, Stigsson L, Eberhardt JL et al (1990) Disease activity and joint damage progression in early rheumatoid arthritis: relation to IgG, IgA, and IgM rheumatoid factor. Ann Rheum Dis 49:906–909PubMedCrossRefGoogle Scholar
  7. 7.
    Ateş A, Kinikli G, Turgay M, Akay G, Tokgöz G (2007) Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: a comparative study. Clin Rheumatol 26:538–545PubMedCrossRefGoogle Scholar
  8. 8.
    del Val del Amo N, Ibanez Bosch R, Fito Manteca C, Gutierrez Polo R, Loza Cortina E (2006) Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin Exp Rheumatol 24:281–286PubMedGoogle Scholar
  9. 9.
    Miriovsky BJ, Michaud K, Thiele GM, O’Dell JR, Cannon GW, Kerr G et al (2010) Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. Ann Rheum Dis 69:1292–1297PubMedCrossRefGoogle Scholar
  10. 10.
    Serdaroğlu M, Cakirbay H, Değer O, Cengiz S, Kul S (2008) The association of anti-CCP antibodies with disease activity in rheumatoid arthritis. Rheumatol Int 28:965–970PubMedCrossRefGoogle Scholar
  11. 11.
    Prevoo MLL, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM (1995) Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRefGoogle Scholar
  12. 12.
    Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 42:244–257CrossRefGoogle Scholar
  13. 13.
    Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K et al (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7:R796–R806PubMedCrossRefGoogle Scholar
  14. 14.
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRefGoogle Scholar
  15. 15.
    De Rycke L, Verhelst X, Kruithof E, Van den Bosch F, Hoffman IE, Veys EM et al (2005) Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 64:299–302PubMedCrossRefGoogle Scholar
  16. 16.
    Alarcon GS, Schrohenloher RE, Bartolucci AA, Ward JR, Williams HJ, Koopman WJ (1990) Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression. Arthritis Rheum 33:1156–1161PubMedCrossRefGoogle Scholar
  17. 17.
    Thoen J, Helgetveit K, Forre O, Haile Y, Kass E (1988) Effects of piroxicam and D-penicillamine on T lymphocyte subpopulations, natural killer cells and rheumatoid factor production in rheumatoid arthritis. Scand J Rheumatol 17:91–102PubMedCrossRefGoogle Scholar
  18. 18.
    Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A et al (2004) Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 63:1218–1221PubMedCrossRefGoogle Scholar
  19. 19.
    Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN et al (2006) The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 65:35–39PubMedCrossRefGoogle Scholar
  20. 20.
    Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G (2006) Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 65:453–458PubMedCrossRefGoogle Scholar
  21. 21.
    Bland JM, Altman DG (1996) Transforming data. BMJ 312:770PubMedCrossRefGoogle Scholar
  22. 22.
    Sokka T, Hetland ML, Mäkinen H, Kautiainen H, Hørslev-Petersen K, Luukkainen RK et al (2008) Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum 58:2642–2651PubMedCrossRefGoogle Scholar
  23. 23.
    Mäkinen H, Hannonen P, Sokka T (2006) Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. Clin Exp Rheumatol 24(Suppl 43):S22–S28Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Jung-Yoon Choe
    • 1
  • Jisuk Bae
    • 2
  • Hwajeong Lee
    • 1
  • Sang-Cheol Bae
    • 3
  • Seong-Kyu Kim
    • 1
  1. 1.Division of Rheumatology, Department of Internal MedicineArthritis and Autoimmunity Research Center, Catholic University of Daegu School of MedicineDaeguRepublic of Korea
  2. 2.Department of Preventive MedicineCatholic University of Daegu School of MedicineDaeguKorea
  3. 3.Clinical Research Center for Rheumatoid ArthritisHanyang University Hospital for Rheumatic DiseasesSeoulRepublic of Korea

Personalised recommendations